Avenue therapeutics announces publication in drug development research highlighting first-in-class preclinical data of baer-101 in a translational model of absence epilepsy

-in vivo data supports baer-101's unique ability to significantly suppress seizures using the synapcell's genetic absence epilepsy rat from strasbourg (“gaers”) model of absence epilepsy- -in vivo data supports baer-101's unique ability to significantly suppress seizures using the synapcell's genetic absence epilepsy rat from strasbourg (“gaers”) model of absence epilepsy-
ATXI Ratings Summary
ATXI Quant Ranking